[Albumin-myoestatosis gauge assisted by an artificial intelligence tool as a prognostic factor in patients with metastatic colorectal-cancer].

Objectives

to evaluate the prognostic role of the marker albumin-myosteatosis (MAM) in Caucasian patients with metastatic colorectal cancer. Material and methods: this study involved 55 consecutive Caucasian patients diagnosed with metastatic colorectal cancer. CT scans at the L3 vertebral level were analyzed to determine skeletal muscle cross-sectional area, skeletal muscle index (SMI), and skeletal muscle density (SMD). Bioelectrical impedance analysis (BIA) (phase angle, reactance, resistance, and SMI-BIA) was used. Albumin and prealbumin were measured. The albumin-myosteatosis marker (AMM = serum albumin (g/dL) × skeletal muscle density (SMD) in Hounsfield units (HU) was calculated. Survival was estimated using the Kaplan-Meier method and comparisons between groups were performed using the log-rank test.

Results

the median age was 68.1 ± 9.1 years. Patients were divided into two groups based on the median MAM (129.1 AU for women and 156.3 AU for men). Patients in the low MAM group had significantly reduced values of phase angle and reactance, as well as older age. These patients also had higher rates of malnutrition by GLIM criteria (odds ratio: 3.8; 95 % CI = 1.2-12.9), low muscle mass diagnosed with TC (odds ratio: 3.6; 95 % CI = 1.2-10.9) and mortality (odds ratio: 9.82; 95 % CI = 1.2-10.9). The Kaplan-Meir analysis demonstrated significant differences in 5-year survival between MAM groups (patients in the low median MAM group vs. patients in the high median MAM group), (HR: 6.2; 95 % CI = 1.10-37.5).

Conclusion

the marker albumin-myosteatosis (MAM) may function as a prognostic marker of survival in Caucasian patients with metastatic CRC.